238 related articles for article (PubMed ID: 31907854)
1. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
2. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
3. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
4. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
[TBL] [Abstract][Full Text] [Related]
5. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).
M'Kada H; Munteanu M; Perazzo H; Ngo Y; Ramanujam N; Imbert-Bismut F; Ratziu V; Bonnefont-Rousselot D; Souberbielle B; Schuppe-Koistinen I; Poynard T;
Regul Toxicol Pharmacol; 2011 Aug; 60(3):290-5. PubMed ID: 21539883
[TBL] [Abstract][Full Text] [Related]
6. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.
Lin X; Parks D; Painter J; Hunt CM; Stirnadel-Farrant HA; Cheng J; Menius A; Lee K
Drug Saf; 2012 Oct; 35(10):865-75. PubMed ID: 22928730
[TBL] [Abstract][Full Text] [Related]
7. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.
Fontana RJ; Hayashi PH; Barnhart H; Kleiner DE; Reddy KR; Chalasani N; Lee WM; Stolz A; Phillips T; Serrano J; Watkins PB;
Am J Gastroenterol; 2015 Oct; 110(10):1450-9. PubMed ID: 26346867
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
Xu HM; Chen Y; Xu J; Zhou Q
World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
[TBL] [Abstract][Full Text] [Related]
9. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Parks D; Lin X; Painter JL; Cheng J; Hunt CM; Spraggs CF; Nelson JJ; Curtis L; Menius JA; Lee KR
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):571-8. PubMed ID: 23300062
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
11. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Kwo PY; Cohen SM; Lim JK
Am J Gastroenterol; 2017 Jan; 112(1):18-35. PubMed ID: 27995906
[TBL] [Abstract][Full Text] [Related]
12. Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
Wernicke J; Pangallo B; Wang F; Murray I; Henck JW; Knadler MP; D'Souza DN; Uetrecht JP
Curr Drug Saf; 2008 May; 3(2):132-42. PubMed ID: 18690991
[TBL] [Abstract][Full Text] [Related]
13. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
[TBL] [Abstract][Full Text] [Related]
14. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
Church RJ; Watkins PB
Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Watkins PB; Desai M; Berkowitz SD; Peters G; Horsmans Y; Larrey D; Maddrey W
Drug Saf; 2011 Mar; 34(3):243-52. PubMed ID: 21332248
[TBL] [Abstract][Full Text] [Related]
16. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
Sorbi D; Boynton J; Lindor KD
Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
[TBL] [Abstract][Full Text] [Related]
17. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials.
Kuffner EK; Temple AR; Cooper KM; Baggish JS; Parenti DL
Curr Med Res Opin; 2006 Nov; 22(11):2137-48. PubMed ID: 17076974
[TBL] [Abstract][Full Text] [Related]
19. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
[TBL] [Abstract][Full Text] [Related]
20. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
